KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average) (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $138.2 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 6.59% year-over-year to $138.2 million; the TTM value through Mar 2026 reached $138.2 million, up 6.59%, while the annual FY2025 figure was $134.7 million, 5.51% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $138.2 million in Q1 2026 for Alnylam Pharmaceuticals, up from $134.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $138.2 million in Q1 2026 and bottomed at $120.4 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $126.9 million, with a median of $126.1 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 1.63% in 2024 and then grew 6.59% in 2026.
  • Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $121.7 million in 2022, then rose by 2.64% to $124.9 million in 2023, then grew by 2.2% to $127.7 million in 2024, then increased by 5.51% to $134.7 million in 2025, then increased by 2.63% to $138.2 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $138.2 million, $134.7 million, and $134.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.